Earnings Winners And Losers: JNJ, RMD, BIM, STJ, ABT, ISRG, DHR
This article was originally published in Clinica
Executive Summary
In this earnings review, we pick out the high achievers and underperformers from this week’s wave of companies that have released their quarterly results, as well as highlight developments that would keep them on a bull run or set them back a few paces.
You may also be interested in...
St. Jude Warns Of Battery-Depletion Issues With Some ICDs
St. Jude Medical has issued a warning about premature battery depletion issues in some ICDs, but says it has already fixed the problem. Analysts say it is not likely to have any impact on Abbott’s plans to acquire St. Jude by the end of 2016.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.